HomeLatest NewsTop 5 Expert Stock Recommendations for Optimal Investments

Top 5 Expert Stock Recommendations for Optimal Investments

Pfizer Bags Jefferies Buy Call After Guidance Cut: 5 Big Analyst Picks

Pfizer upped Jefferies after guidance cut

Pfizer shares soared after analysts issued positive notes following the healthcare giant’s lowered revenue and earnings forecasts for the year. The decline in demand for its COVID-19 treatment, Paxlovid, led Pfizer to revise its adjusted EPS to $1.55 from $3.35 and full-year revenue to $59.5 billion from $68.5 billion. However, Jefferies responded favorably to the revised guidance by upgrading Pfizer’s rating from Hold to Buy with a price target of $39.00, citing factors such as exceeding buy-side expectations for Comirnaty, cost reductions, promising investor catalysts, and the anticipated closing of the SGEN deal.

- Advertisement -

Wayfair shares goosed on upgrade

Wayfair shares jumped after Loop Capital upgraded the company to Hold from Sell and raised its price target to $50.00 from $25.00. Bernstein had also recently upgraded Wayfair to Market Perform from Underperform, projecting improved revenue growth and margin commentary. With Wayfair set to report its Q3/23 earnings soon, the company’s stock is expected to continue its positive momentum.

Instacart gets several buy initiations

- Advertisement -

Following Instacart’s IPO, multiple Wall Street firms initiated coverage on the company, with most giving it buy-equivalent ratings. Citi began its analysis with a Buy rating and a price target of $34.00, highlighting Instacart’s strong tech partnerships, coverage of 95% of North American households, and potential for growth through customer acquisition. Stifel also started coverage with a buy rating and a price target of $48.00. Other firms, including Piper Sandler, JPMorgan, and Barclays, initiated coverage with Overweight ratings and price targets ranging from $33.00 to $40.00.

Two more upgrades

Morgan Stanley upgraded Nice to Overweight from Equalweight with a price target of $220.00, while JPMorgan upgraded Nucor to Neutral from Underweight with a price target of $151.00. These upgrades reflect positive sentiments towards both companies’ prospects.

Investing.com subscribers received this news first. To stay ahead of the market and receive real-time updates, join InvestingPro.

With fast-moving markets, being one step ahead is crucial. InvestingPro subscribers are always well-informed with lightning-quick updates. Be the first to know by joining InvestingPro.

Must Read